Evidence map›Paper›PMID 39543711›Full record

ArticleJournal of translational medicine2024

Comparison of functional characterization of cancer stem cells in different tumor tissues of pseudomyxoma peritonei.

Haipeng Zhou, Hongbin Xu, Shaojun Pang, Lubiao An, Guanjun Shi, Chong Wang, Pu Zhang, Xiwen Fan, Jing Yang, Shiyi Tang and 4 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Haipeng ZhouDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.ORCID 0000-0002-2240-5362
Hongbin XuDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Shaojun PangDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Lubiao AnDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Guanjun ShiDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Chong WangDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Pu ZhangDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Xiwen FanDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Jing YangSpace Medical Center, Aerospace Center Hospital, Beijing, 100049, China.
Shiyi TangSpace Medical Center, Aerospace Center Hospital, Beijing, 100049, China.
Yiyan LuDepartment of Pathology, Aerospace Center Hospital, Beijing, 100049, China.
Lifei YuDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Feng ChenDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China.
Ruiqing MaDepartment of Myxoma, Aerospace Center Hospital, Beijing, 100049, China. maruiqing2014@126.com.

Funding

Beijing Gold-Bridge Project ZZ21043Sponsored by Science Foundation of AMHT 2023YK06
6 · The paper itself

Abstract

backgroundPseudomyxoma peritonei (PMP) is a rare malignant peritoneal tumor that readily recurs and metastasizes. Studies have shown that cancer stem cells (CSCs) play an important role in tumor recurrence, metastasis, and prognosis.

objectiveIn this study, our aim was to isolate CSCs from various tissues of PMP patients and compare their proliferation, migration, and anti-inflammatory abilities.

methodsWe identified CSCs subsets with markers CD133

resultsCSCs content was highest in the appendiceal tumor tissue and lowest in the mucous tissue. The cell viability rate of the sorted CSCs was above 98%, and the positive rate of CD133

conclusionAC in patients was more inert and anti-inflammatory, whereas abdominal cavity MC and PC were more active. This study revealed the biological characteristics of CSCs in different tumor tissues of patients with PMP, providing a reference for future targeted CSCs therapy.

Indexed as

Cell ProliferationNeoplastic Stem CellsPseudomyxoma PeritoneiAC133 AntigenAgedCell MovementCell SurvivalFemaleHumansMaleMiddle AgedPeritoneal NeoplasmsAC133 AntigenCancer stem cellsCell functionCell sortingPseudomyxoma peritoneiSingle-cell RNA sequencing

Identifiers

PMID39543711
PMCPMC11566827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.